Pathstone Family Office’s Pacific Biosciences PACB Stock Holding History

Pathstone Family Office’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$102K	Sell	12,231 -4,628	-27%	-$52.9K	﹤0.01%	1585
2023 Q2	$226K	Sell	16,859 -997	-6%	-$12.1K	﹤0.01%	1093
2023 Q1	$207K	Sell	17,856 -21,962	-55%	-$218K	﹤0.01%	1077
2022 Q4	$326K	Sell	39,818 -3,918	-9%	-$33.8K	﹤0.01%	1227
2022 Q3	$254K	Buy	43,736 +21,129	+93%	+$121K	﹤0.01%	1272
2022 Q2	$99.9K	Buy	22,607 +12,303	+119%	+$74.8K	﹤0.01%	993
2022 Q1	$94K	Sell	10,304 -37	-0.4%	-$426	﹤0.01%	925
2021 Q4	$212K	Buy	10,341 +1,406	+16%	+$33.9K	0.01%	822
2021 Q3	$228K	Buy	8,935 +1,394	+18%	+$41.3K	0.01%	772
2021 Q2	$264K	Buy	+7,541	New	+$219K	0.01%	689
2021 Q1	–	Sell	-1,500	Closed	-$39K	–	1150
2020 Q4	$39K	Buy	+1,500	New	+$25.5K	﹤0.01%	561

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Pathstone Family Office's PACB Position: Q3 2023 in Review

Pathstone Family Office reduced its Pacific Biosciences (PACB) stake by 27% in Q3 2023, selling an estimated $52.9K and leaving 12,231 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #1585.

Pathstone Family Office first reported a position in PACB in Q4 2020 and has held it in 11 quarters since. The position peaked at $326K in Q4 2022. 274 funds tracked by Wall St. Rank hold PACB as of Q3 2023.

Pathstone Family Office held 12,231 shares of Pacific Biosciences worth $102K as of Q3 2023.
Pathstone Family Office sold 4,628 Pacific Biosciences shares in Q3 2023, an estimated $52.9K.
Pacific Biosciences made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1585 holding.
Pathstone Family Office first reported a position in Pacific Biosciences in Q4 2020 and has held it in 11 quarters since.
Pathstone Family Office's Pacific Biosciences position peaked at $326K in Q4 2022.
274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.